Which, if any, antihypertensive agents cause cancer?

Current Opinion in Cardiology

Volumn 27, Issue 4, 2012, Pages 374-380

  Singh, Amita ^a   Bangalore, Sripal ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin receptor blockers; antihypertensive agents; cancer

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT;

ANGIOGENESIS; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; COLON POLYP; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG MEGADOSE; ESOPHAGUS CANCER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL CARCINOMA; HEPATOBILIARY SYSTEM CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MEDICAL LITERATURE; MEDICAL PRACTICE; MELANOMA; META ANALYSIS (TOPIC); METHODOLOGY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

EID: 85027926808     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328353bc4f     Document Type: Review

References (44)

1. Rabin R. Blood pressure drugs are tied to cancer. The New York Times 21 June 2010; Section Science.
2. Sipahi I, Debanne S, Rowland D, et al. Angiotensin-receptor blockade and risk of cancer: Meta-Analysis of randomised controlled trials. Lancet Oncol 2010; 11:627-636.
3. Bangalore S, Kumar S, Kjeldsen S, et al. Antihypertensive drugs and risk of cancer: Network meta-Analyses and trial sequential analyses of 324168 participants from randomised trials. Lancet Oncol 2010; 12:65-82.
4. Armstrong B, Skegg D, White G, Doll R. Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 1976; 2:8-12.
5. O'Fallon W, Labarthe D, Kurland L. Rauwolfia derivates and breast cancer. Lancet 1975; 306:292-296.
6. Grossman E, Messerli F, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83:1090-1093.
7. Jiang X, Castelao J, Yuan J, et al. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis 2010; 31:1964-1971.
8. George A, Thomas W, Hannan R. The renin-Angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer 2010; 10:745-759.
9. Deshaves F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005; 16:293-299.
10. Barron T, Connoly R, Sharp L, et al. Beta blockers and breast cancer mortality: A population based study. J Clin Oncol 2011; 29:2635-2644.
11. Friedman G, Udaltsova N, Habel L. Norepiphrine antagonists and cancer risk. Int J Cancer 2011; 128:736-738.
12. Mason RP. Calcium channel blockers, apoptosis and cancer: Is there a biologic relationship? J Am Coll Cardiol 1999; 34:1957-1966.
13. Pahor M, Guralnik J, Salive M, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 4:695-699.
14. McMurray J, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: The CHARM-Added Trial. Lancet 2003; 362:767-771.
15. Pfeffer M, Swedberg K, Granger C, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall Program. Lancet 2003; 362:759-766.
16. Yu M, Mack T, Hanish R, et al. Cigarette smoking, obesity, diuretic use and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986; 77:351-356.
17. McLaughlin J, Blot W, Fraumeni J. Diuretics and renal cell cancer. J Natl Cancer Inst 1988; 80:378.
18. Schottenfield D, Fraumeni J. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006. pp. 497-498.
19. Loffing K, Loffing-Cueni D, Hegyi I, et al. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996; 50:1180-1190.
20. Flaherty K, Fuchs C, Colditz G, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma. Cancer Causes Control 2005; 16:1099-1106.
21. ALLHAT. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002; 288:2981-2997.
22. Zhang D, Ma Q, Hu H, Zhang M. Beta-2 adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFKB and AP-1. Cancer Biol Ther 2010; 10:19-29.
23. Largent J, Bernstein L, Horn-Ross P, et al. Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study Cohort. Cancer Causes Control 2010; 21:1615-1624.
24. MRC. Medical Research Council Trial of treatment of hypertension in older adults: Principal results. BMJ 1992; 304:405-412.
25. Cohen H, Pieper C, Hanlon J, et al. Calcium channel blockers and cancer. Am J Med 2000; 108:210-215.
26. Boudreau D, Koehler E, Rulyak S, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:3076-3080.
27. Debes J, Roberts R, Jacobson D, et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 2004; 13:255-259.
28. Neo J, Malcontenti-Wilson C, Muralidhan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007; 22:577-584.
29. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7:1073-1078.
30. Yasumatsu R, Nakashima T, Masuda M, et al. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 2004; 130:567-573.
31. Kedika R, Patel M, Pena-Sahdala H, et al. Longterm use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 2011; 45:12-16.
32. Khurana V, Bejjanki H, Caldito G. Angiotensin converting enzyme inhibitors reduce the incidence of colon cancer: A study of half a million US veterans. http://www.congressomedico.it/congressi/2006/ddw/23-mag-Art2-Abs1. asp2006. [Accessed 14 December 2011]
33. Khurana V, Kyanam K, Caldito G. Angiotensin converting enzyme inhibitors reduce the incidence of esophageal cancer: A study of half a million US veterans. http://www.congressomedico.it/congressi/2006/ddw/23-mag-Art2-Abs1. asp2006. [Accessed 14 December 2011]
34. Khurana V, Sheth A, Caldito G, Barkin J. Angiotensin Converting Enzyme Inhibitors Reduce The Incidence Of Pancreatic Cancer: A Study Of Half A Million US Veterans. http://www.congressomedico.it/congressi/2006/ddw/23-mag-Art2-Abs1. asp2006. [Accessed 14 December 2011]
35. SOLVD Investigators. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
36. Coleman C, Baker W, Kluger J, White C. Antihypertensive medication and their impact on cancer incidence: A mixed treatment comparison meta-Analysis of randomized controlled trials. J Hypertens 2008; 22:622-629.
37. Trialists ARB. Effects of Telmisartan, Irbesartan, Valsartan, Candesartan, and Losartan on Cancers in 15 trials enrolling 138769 individuals. J Hypertens 2011; 29:623-635.
38. Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-Angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010; 103:1644-1648.
39. Walther T, Menrad A, Orzechowsi H, et al. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003; 17:2061-2067.
40. Clere N, Corre I, Faure S, et al. Deficiency or blockade of angiotensin II receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 2010; 127:2279-2291.
41. Chang C, Lin J, Lai M. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. J Clin Oncol 2011; 29:3001-3007.
42. Pasternak B, Svanstrom H, Callreus T, et al. Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123:1729-1736.
43. US Food and Drug Administration. FDA drug safety communication: No increase in risk of cancer with certain blood pressure drugs: Angiotensin receptor blockers (ARBs). http://www.fda.gov/Drugs/DrugSafety/ucm257516.htm2011. [Accessed 3 June 2011]
44. Hallas J, Christensen R, Andersen M, et al. Long-term use of drugs affecting the renin-Angiotensin system and the risk of cancer: A population-based casecontrol study. Br J Clin Pharmacol 2012; 73:1-21.